
Canine Mast Cell Tumors: a clinical approach and updates on medical management

Overview


Grading Different grading schemes

- Origent grading schemes
 Progrostic panels?
 Post-operative treatments
 Radiation, electrochemotherapy, chemotherapy
 Inoperable MCTs
 New and newish therapies
- Stelfonta Gilvetmab Autologous vaccines?



Mast cell tumor grading

- Cutaneous tumors*
 Best predictor of biologic behavior BUT NOT PERFECT!
 Patnaik grading system
 - naik grading system Grades 1-3 Cytoplasmic boundaries, mitoses, granularity, nuclear/cellular shape Grade 2 (intermediate grade) tumors? Inter-pathologist disagreement



Mast cell tumor grading

- Kiupel grading
 Low vs. high grade
 High grade criteria
 _ 2 / mitoses/10 hpf
 _ 2 8 bizare nucle// 10 hpf
 _ 3 multinucleated cells/ 10 hpf
 karyomegaly
 More accurately predicts biologic More accurately predicts biologic
 - behavior!
- Both grades on biopsy reports



Mast cell tumor grading


Clinical application


- nical application What is provided on a biopsy report? Margins Patnaik grade Kiupel grade Mitotic count Location of tumor Call your local oncologist*



Mast cell tumor grading

- Prognostic panel
- GITOSTIC Partier Ki67 Argyrophilic nucleolar organizer regions (AgNORs) Proliferating cell nuclear antigen (PCNA) Kit immunostaining c-Kit mutation status
- Clinical use and interpretation?





Post-operative treatments

- To treat or not to treat? • Treating for LOCAL
- RECURRENCE for incompletely
- excised tumors Recurrence rate between 10-30% Scar revision surgery? Radiation therapy Electrochemotherapy Chemotherapy?



Post-operative treatments

- Treating for <u>LOCAL RECURRENCE</u> for incompletely excised tumors
- Radiation therapy (RT)

 - Definitive protocols Expected local cure for low to intermediate grade tumors Effective long term control in high grade

 - setting Acute side effects Coarsely fractionated protocols?





Post-operative treatments

- Treating for LOCAL RECURRENCE for



Post-operative treatments

- Treating for <u>LOCAL</u>
 <u>RECURRENCE</u> for incompletely excised tumors
- Medical therapy/Chemotherapy? Not typically considered



Post-operative treatments

- High grade mast cell tumors
 Onsider local therapy if incomplete
 - excision excision 50-95% metastatic rate Systemic therapy is warranted* Vinblastine Lomustine Palladia



Post-operative treatments

- High grade mast cell tumors
- Vinblastine (VBL) Gold standard
- Goio standard Once every week x 4, then every other week x 4 Post-operative tx MST = 3.8 yrs 70% 1- and 2-year disease free
- intervals Current national backorder



Post-operative treatments

- High grade mast cell tumors • Lomustine (CCNU)

 - Second line
 Myelosuppressive, hepatotoxic
 Hosoya et al. 2009→100% and 77% 1- and 2- year disease free
 - intervals
 Hay and Larson, 2019 → MST



Post operative treatments

- High grade mast cell tumors
 Palladia (toceranib phosphate)?
- Receptor tyrosine kinase inhibitor
- Use in microscopic disease?
- Adverse events



Inoperable MCTs

Radiation therapy Hypofractionated protocols Typically once weekly x 4 76% = 85% overall response rate Combine with Palladia* Treatment of the local lymph node Degranulation



Inoperable MCTs

• Chemotherapy

- Downstage disease Vinblastine 78% partial response
- rate Lomustine Chlorambucil Palladia*

- Practical for chronic use Prednisone



Inoperable MCTs

• Chemotherapy



New therapies

• Stelfonta®

- Tigilanol tiglate Non-metastatic cutaneous and SQ
- von-metastatic cutaneous and tumors* > 1 cm in diameter, < 10 cm3 Dose = 0.5 ml per cm3 Retreat in 28 d if resolution not

- achieved Steroid and antihistamine pre-treatment! Care with handling and injecting!



New therapies

- Stelfonta
 - Stelfonta

 o
 De Ridder et al., JVIM, 2021.

 75% complete response (CR) at 28 d

 o
 No recurrence in 93% at 84 d

 o
 Additional dose achieved CR in 8 dogs

 o
 Wound formation associated with efficacy


 o
 Off label use in horses





New therapies

- Gilvetmab
 - Monoclonal antibody Binds PD-L1
 - Binds PD-L1
 Conditionally licensed for melanomas and MCTs
 Limited data
 Limited availability
 Very expensive






Multiple MCTs

- Brachycephalic breeds, Pit Bulls, Labradors

- Typically low grade
 Staging for repeat offenders?
 Surgery ¥
 Systemic therapy?



Histamine blocking therapies

- H1 blockers anti-anaphylactic
 H2 blockers Gl protective
 Active ulceration?

 Sucraffate, misoprostol
 Use for gross disease!
 Unknown benefit in microscopic disease setting
 NOT throught to be antineolastic
- neoplastic



References

• Available upon request!



